Get to know our clinical trials
Efficacy and safety trial of Tumor Treating Fields, atezolizumab, gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic carcinoma.
EFFICACY AND SAFETY TRIAL OF TUMOR TREATING FIELDS, ATEZOLIZUMAB, GEMCITABINE AND NAB-PACLITAXEL AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC CARCINOMA
Technical Summary
- PRELIMINARY, SINGLE-GROUP, PRELIMINARY STUDY OF THE CONCOMITANT USE OF ELECTRIC FIELDS FOR TUMOR TREATMENT (TTFIELDS, 150 KHZ) AND ATE-ZOLIZUMAB, GEMCITABINE AND NAB-PACLITAXEL AS FIRST-LINE TREATMENT OF METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (ADPM)
- Code EudraCT: 2022-003157-55
- Protocol number: EF-39 (PANOVA-4)
- Promoter: NovoCure Ltd
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.